| Overall survival | ||||||
| Study | Groups | Median (weeks) | 95% CI | P value | Hazard Ratio (95% CI) | |
| Meier 2009 | Overall | Topotecan | 55.0 | 50.0 ‐ 65.6 | 0.0023 | 1.49 (95% CI 1.15 ‐ 1.93) |
| Treosulfan | 41.0 | 34.0 ‐ 58.4 | ||||
| Stratum 1 | Topotecan | 48.7 | 31.9 ‐ 54.4 | 0.1111 | ||
| (platinum‐resistant participants) | Treosulfan | 31.6 | 27.4 ‐ 35.4 | |||
| Stratum 2 | Topotecan | 69.1 | 55.3 ‐ 88.7 | 0.0068 | ||
| (platinum‐sensitive participants) | Treosulfan | 59.3 | 41.0 ‐ 74.6 | |||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.